CN Patent

CN102282129A — 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂

Assigned to AbbVie Inc · Expires 2011-12-14 · 14y expired

What this patent protects

公开了抑制抗凋亡的Bcl-2蛋白的活性的化合物、含有该化合物的组合物和治疗疾病的方法，在该疾病期间，抗凋亡Bcl-2蛋白被表达。

USPTO Abstract

公开了抑制抗凋亡的Bcl-2蛋白的活性的化合物、含有该化合物的组合物和治疗疾病的方法，在该疾病期间，抗凋亡Bcl-2蛋白被表达。

Drugs covered by this patent

Patent Metadata

Patent number
CN102282129A
Jurisdiction
CN
Classification
—
Expires
2011-12-14
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.